ClinicalTrials.gg
CompletedNCT06594159Updated Apr 3, 2025

A Study of LY4065967 in Healthy Japanese Participants

A Phase 1 interventional study of LY4065967 and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Japan. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants. Blood tests will be performed to check how much LY4065967 and rosuvastatin get into the bloodstream and how long it takes the body to eliminate it. This is a 3-part study and will last approximately 2 weeks excluding screening period for each part.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese participants who are overtly healthy as determined by medical evaluation including medical history and physical examination
  • Have a within the range 18 to 30 kilogram per square meter (kg/m2)
  • Have a body weight of:
  • ≥ 40 kilograms (kg) for individuals assigned female at birth
  • ≥ 50 kg for individuals assigned male at birth

Exclusion criteria

Exclusion Criteria:

  • Have a history or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or neurological disease, or convulsions that, in the judgment of the investigator, indicate a medical problem that would preclude study participation
  • Have an abnormality in the 12-lead echocardiogram () that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have a history of multiple or severe drug allergies or severe posttreatment reactions, which in the opinion of the investigator may hamper participation in the study
  • Show evidence of and/or have a positive hepatitis C virus antibody test
  • Show evidence of (HIV) infection and/or positive HIV antigen and/or antibodies.
  • Show evidence of and/or positive hepatitis B surface antigen
  • Show evidence of syphilis or have a positive syphilis test.
  • Have an abnormal blood pressure (supine) as determined by the investigator
  • Are pregnant or intend to become pregnant or to breastfeed during the study.
  • Participants with a history of drug abuse which, in the opinion of the investigator, is clinically significant or who test positive for drugs of abuse at screening or admission
  • Have alcohol intake that exceeds recommended average weekly alcohol consumption limits per local regulation, or an amount deemed significant by the investigator
  • Smoke more than 10 cigarettes per day or the equivalent including electronic cigarettes
  • Are unwilling to comply with the dietary restrictions required for this study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    LY4065967 Part A

    A single dose of LY4065967 administered orally

    Drug: LY4065967

  • Placebo comparator
    Placebo Part A

    Placebo administered orally

    Drug: Placebo

  • Experimental
    LY4065967 Part B

    Multiple doses of LY4065967 administered orally

    Drug: LY4065967

  • Placebo comparator
    Placebo Part B

    Placebo administered orally

    Drug: Placebo

  • Experimental
    LY4065967 and Rosuvastatin Part D

    LY4065967 and Rosuvastatin administered orally

    Drug: LY4065967 · Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug Administration

    Part A: A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline to 7 Days

  2. Part B: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug Administration

    Part B: A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline to 12 Days

  3. Part D: PK: Maximum Concentration (Cmax) of Rosuvastatin

    Part D: PK: Cmax of Rosuvastatin

    Time frame: Predose on Day 1 Through 72 Hours Post-Dose

  4. Part D: PK: Area Under the Concentration Versus Time Curve (AUC) of Rosuvastatin

    Part D: PK: AUC of Rosuvastatin

    Time frame: Predose on Day 1 Through 72 Hours Post-Dose

Secondary outcomes

  1. Part A : Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4065967

    Part A: PK: Cmax of LY4065967

    Time frame: Predose on Day 1 Through 48 Hours Post-Dose

  2. Part B: PK: Cmax of LY4065967

    Part B: PK: Cmax of LY4065967

    Time frame: Predose on Day 1 Through Day 9

  3. Part A and B: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4065967

    Part A and B: PK: AUC of LY4065967

    Time frame: Predose on Day 1 Through 48 Hours Post-Dose

  4. Part D: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4065967

    Part D: PK: Cmax of LY4065967

    Time frame: Day 5 Through Day 11

  5. Part D: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4065967

    Part D: PK: AUC of LY4065967

    Time frame: Day 5 Through Day 11

07

Study locations

1 site
  • Souseikai Fukuoka Mirai Hospital
    Fukuoka, 813-0017, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Mar 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2024
First posted
Sep 19, 2024
StartActual
Oct 22, 2024
Primary completionActual
Mar 11, 2025
CompletionActual
Mar 11, 2025
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06594159
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 22, 2024
Primary completion
Mar 11, 2025
Completion
Mar 11, 2025
Last update
Apr 3, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY4065967

Start the discussion